Tag: Intercepts
Intercept’s NASH hopeful spurned by FDA, raising questions for other companies...
Intercept Therapeutics, long the frontrunner in non-alcoholic steatohepatitis (NASH), has suffered several delays on its FDA application for obeticholic acid (OCA). Now, the company has received an...
Intercept’s hotly anticipated NASH drug has to wait for its FDA...
Intercept Pharmaceuticals and its closely watched nonalcoholic steatohepatitis (NASH) candidate have hit another snag, this one courtesy of the coronavirus pandemic.
The FDA has put...
